Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

Assistance Publique - Hôpitaux de Paris240 enrolled

Overview

Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients

Study Type

OBSERVATIONAL

Enrollment

240

Conditions

Pneumocystis Immunocompromised Patients

Interventions

Biological samplingOTHER

Mouthwash, nasopharyngeal swab, blood sampling

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * adult patients with suspected pneumocystis * with an indication for bronchial fibroscopy for BAL or induced sputum * no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition Exclusion Criteria: * Pneumocystis treated for more than 72 hours * pregnancy/breast-feeding * adult patients deprived of liberty, protected

Locations (4)

Hôpital Lariboisière AP-HP Maladies infectieuses

Paris, France

RECRUITING

Hôpital Saint Louis AP-HP Maladies infectieuses

Paris, France

RECRUITING

Hôpital Saint Louis AP-HP Réanimation

Paris, France

RECRUITING

Outcomes

Primary Outcomes

Pearson correlation coefficient

Pearson correlation coefficient between the fungal load obtained by PCR on nasopharyngeal swabs nasopharyngeal swab and buccal lavage and that obtained by reference samples (induced sputum or BAL) in patients with confirmed PcP.

Time frame: At inclusion